Teva offers to buy rival Mylan for $40 billion | Fortune
Big blow for Teva as FDA approves Mylan's generic Copaxone - Globes
Drugmaker Teva makes $40B bid for rival Mylan
Mylan Rejects Teva Takeover Bid As Too Low | Mint
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
Teva Pharmaceutical Industries Ltd. ends its hostile bid for Mylan NV - Pittsburgh Business Times
$40B deal: Teva offers to buy Mylan
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats | Fierce Pharma
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Teva Issues New Letter to Mylan NV Confirming Seriousness Of Offer To Acquire Mylan - Jewish Business News
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Generic EpiPen Cleared By FDA As Teva Challenges Mylan
Israel-Based Teva Pharmaceutical Industries Smacks Down With Mylan With $40B Bid - YouTube
Mylan shares soar after takeover proposal
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Mylan Should Try Teva On for Size - WSJ
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva's Copaxone holds its own in wake of Mylan's generic price cut | Fierce Pharma
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Teva makes $40B offer for Mylan
Teva Makes Hostile Bid To Acquire Mylan
